EA010240B1 - 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ - Google Patents
1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ Download PDFInfo
- Publication number
- EA010240B1 EA010240B1 EA200401100A EA200401100A EA010240B1 EA 010240 B1 EA010240 B1 EA 010240B1 EA 200401100 A EA200401100 A EA 200401100A EA 200401100 A EA200401100 A EA 200401100A EA 010240 B1 EA010240 B1 EA 010240B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- treatment
- fluoro
- diene
- bph
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0322395A GB0322395D0 (en) | 2003-09-24 | 2003-09-24 | Methods for treating bladder dysfunction and related compounds and compositions |
GB0325598A GB2407499B (en) | 2003-11-03 | 2003-11-03 | Vitamin D3 analogue for use in the treatment of BPH |
GB0416876A GB0416876D0 (en) | 2004-07-29 | 2004-07-29 | Compound and use in treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200401100A1 EA200401100A1 (ru) | 2005-04-28 |
EA010240B1 true EA010240B1 (ru) | 2008-06-30 |
Family
ID=34229055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200401100A EA010240B1 (ru) | 2003-09-24 | 2004-09-23 | 1α-ФТОР-25-ГИДРОКСИ-16,23Е-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1673096A1 (zh) |
JP (2) | JP2007506699A (zh) |
CN (1) | CN100488511C (zh) |
BE (1) | BE1016292A3 (zh) |
BR (1) | BRPI0404050A (zh) |
CH (1) | CH698144B1 (zh) |
EA (1) | EA010240B1 (zh) |
FR (1) | FR2859910B1 (zh) |
HK (1) | HK1085373A1 (zh) |
NL (1) | NL1027109C2 (zh) |
NZ (1) | NZ535531A (zh) |
WO (1) | WO2005027923A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006038611A1 (ja) * | 2004-10-05 | 2006-04-13 | Kissei Pharmaceutical Co., Ltd. | 下部尿路閉塞疾患に伴う蓄尿障害の予防及び/又は治療剤 |
JPWO2006038619A1 (ja) * | 2004-10-06 | 2008-05-15 | キッセイ薬品工業株式会社 | 前立腺肥大症に対する手術療法への移行予防用医薬組成物 |
US20100009949A1 (en) * | 2006-03-24 | 2010-01-14 | Bioxell S.P.A. | Novel method |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
US20120164240A1 (en) | 2010-12-22 | 2012-06-28 | Audino David Lawrence | Enriched a. blitoides compositions and uses thereof |
US20170049834A1 (en) * | 2015-08-18 | 2017-02-23 | Golden Biotechnology Corporation | Benign prostatic hyperplasia add-on therapy |
FR3063906A1 (fr) * | 2017-03-20 | 2018-09-21 | Pierre Fabre Medicament | Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0808833A2 (en) * | 1996-05-23 | 1997-11-26 | F. Hoffmann-La Roche Ag | Vitamin D3 analogs |
US5872113A (en) * | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
US6030963A (en) * | 1995-11-22 | 2000-02-29 | Hoffmann-La Roche Inc. | 16-ene-26,27-bishomo cholecalciferols |
EP1048661A2 (en) * | 1999-04-26 | 2000-11-02 | F. Hoffmann-La Roche Ag | Process for preparing anti-osteoporotic agents |
US6479538B1 (en) * | 1997-05-16 | 2002-11-12 | Women And Infants Hospital | Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
WO2003034961A1 (en) * | 2001-10-23 | 2003-05-01 | Euro-Celtique, S.A. | Terazosin transdermal device and methods |
HUP0501186A2 (en) * | 2001-12-03 | 2006-05-29 | Novacea | Pharmaceutical compositions comprising active vitamin d compounds |
-
2004
- 2004-09-22 BR BR0404050-3A patent/BRPI0404050A/pt not_active IP Right Cessation
- 2004-09-22 CH CH01553/04A patent/CH698144B1/fr not_active IP Right Cessation
- 2004-09-23 NZ NZ535531A patent/NZ535531A/xx unknown
- 2004-09-23 EA EA200401100A patent/EA010240B1/ru not_active IP Right Cessation
- 2004-09-23 FR FR0410073A patent/FR2859910B1/fr not_active Expired - Fee Related
- 2004-09-24 EP EP04765598A patent/EP1673096A1/en not_active Withdrawn
- 2004-09-24 NL NL1027109A patent/NL1027109C2/nl not_active IP Right Cessation
- 2004-09-24 BE BE2004/0472A patent/BE1016292A3/nl not_active IP Right Cessation
- 2004-09-24 JP JP2006527365A patent/JP2007506699A/ja not_active Abandoned
- 2004-09-24 WO PCT/EP2004/010760 patent/WO2005027923A1/en active Application Filing
- 2004-09-24 CN CNB2004100800817A patent/CN100488511C/zh not_active Expired - Fee Related
-
2005
- 2005-09-16 HK HK05108113.0A patent/HK1085373A1/xx not_active IP Right Cessation
-
2008
- 2008-08-18 JP JP2008209429A patent/JP2009035559A/ja not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6030963A (en) * | 1995-11-22 | 2000-02-29 | Hoffmann-La Roche Inc. | 16-ene-26,27-bishomo cholecalciferols |
EP0808833A2 (en) * | 1996-05-23 | 1997-11-26 | F. Hoffmann-La Roche Ag | Vitamin D3 analogs |
US5872113A (en) * | 1997-05-16 | 1999-02-16 | Syntex (U.S.A.) Inc. | Fluorinated vitamin D3 analogs |
US6479538B1 (en) * | 1997-05-16 | 2002-11-12 | Women And Infants Hospital | Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof |
EP1048661A2 (en) * | 1999-04-26 | 2000-11-02 | F. Hoffmann-La Roche Ag | Process for preparing anti-osteoporotic agents |
Also Published As
Publication number | Publication date |
---|---|
WO2005027923A1 (en) | 2005-03-31 |
NZ535531A (en) | 2006-03-31 |
JP2009035559A (ja) | 2009-02-19 |
EA200401100A1 (ru) | 2005-04-28 |
CH698144B1 (fr) | 2009-05-29 |
NL1027109A1 (nl) | 2005-03-29 |
HK1085373A1 (en) | 2006-08-25 |
NL1027109C2 (nl) | 2005-05-03 |
FR2859910B1 (fr) | 2006-04-28 |
EP1673096A1 (en) | 2006-06-28 |
JP2007506699A (ja) | 2007-03-22 |
BRPI0404050A (pt) | 2005-06-14 |
CN100488511C (zh) | 2009-05-20 |
CN1615891A (zh) | 2005-05-18 |
BE1016292A3 (nl) | 2006-07-04 |
FR2859910A1 (fr) | 2005-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10245240B2 (en) | Treatment of prostate carcinoma | |
Numan et al. | Medial preoptic area and onset of maternal behavior in the rat. | |
US20060035867A1 (en) | Methods of treating cancer and the pain associated therewith using endothelin antagonists | |
US20080207769A1 (en) | Method for treating benign prostatic hyperplasia | |
Schneider et al. | Persistent testicular delta5-isomerase-3beta-hydroxysteroid dehydrogenase (delta5-3beta-HSD) deficiency in the delta5-3beta-HSD form of congenital adrenal hyperplasia. | |
Gunson et al. | Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor | |
KR20220045198A (ko) | 에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제 | |
JP2009035559A (ja) | 良性前立腺肥大の治療のためのビタミンd3アナログの使用 | |
WO1998025623A1 (en) | Methods and compositions for preventing and treating bone loss | |
Roylance et al. | Current treatment of BPH | |
Rasmusson et al. | Therapeutic control of androgen action | |
US11986507B1 (en) | Micronutrient composition to improve men's health | |
Utsumi et al. | Effect of estrogen on receptor positive human esophageal carcinoma | |
Shirai et al. | Low Tumorigenic Response to 3, 2′‐Dimethyl‐4‐aminobiphenyl Administration in the Prostate of Rats Castrated at Birth | |
Lau et al. | Effects of Colprone® on in vitro release of androgens from the reproductive organs of the male rat | |
Schenkman et al. | Hormonal Influences on Nephrolithiasis | |
Kohram | Effect of Follicular Synchronization and Hormonal Alterations on Superstimulatory Response and Embryo Production in Cattle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |